Business Description
TDS Pharm Co Ltd
ISIN : KR7464280007
Compare
Compare
Traded in other countries / regions
464280.Korea IPO Date
2024-08-21Description
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.12 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.31 | |||||
| Debt-to-EBITDA | 1.05 | |||||
| Interest Coverage | 16.64 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 6.87 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -66 | |||||
| 3-Year EBITDA Growth Rate | -62.4 | |||||
| 3-Year EPS without NRI Growth Rate | -56.7 | |||||
| 3-Year FCF Growth Rate | -66.2 | |||||
| 3-Year Book Growth Rate | -67.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.75 | |||||
| 9-Day RSI | 38.9 | |||||
| 14-Day RSI | 40.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.43 | |||||
| Quick Ratio | 2.18 | |||||
| Cash Ratio | 1.5 | |||||
| Days Inventory | 38.43 | |||||
| Days Sales Outstanding | 73.92 | |||||
| Days Payable | 37.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -249.2 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 26.43 | |||||
| Operating Margin % | 16.69 | |||||
| Net Margin % | 15.6 | |||||
| FCF Margin % | 10.06 | |||||
| ROE % | 22.73 | |||||
| ROA % | 14.55 | |||||
| ROIC % | 24.69 | |||||
| ROC (Joel Greenblatt) % | 41.17 | |||||
| ROCE % | 26 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.45 | |||||
| PE Ratio without NRI | 12.45 | |||||
| PS Ratio | 1.94 | |||||
| PB Ratio | 2.55 | |||||
| Price-to-Tangible-Book | 2.42 | |||||
| Price-to-Free-Cash-Flow | 19.32 | |||||
| Price-to-Operating-Cash-Flow | 17.72 | |||||
| EV-to-EBIT | 7.52 | |||||
| EV-to-EBITDA | 6.39 | |||||
| EV-to-Revenue | 1.45 | |||||
| EV-to-FCF | 15.2 | |||||
| Price-to-Graham-Number | 1.13 | |||||
| Price-to-Net-Current-Asset-Value | 4.1 | |||||
| Price-to-Net-Cash | 13.41 | |||||
| Earnings Yield (Greenblatt) % | 13.3 | |||||
| FCF Yield % | 4.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TDS Pharm Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 30,049.355 | ||
| EPS (TTM) (â‚©) | 1101 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 40.21 | ||
| 14-Day ATR (â‚©) | 1027.637437 | ||
| 20-Day SMA (â‚©) | 14282.5 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (â‚©) | 11970 - 60700 | ||
| Shares Outstanding (Mil) | 5.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TDS Pharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TDS Pharm Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
TDS Pharm Co Ltd Frequently Asked Questions
What is TDS Pharm Co Ltd(XKRX:464280)'s stock price today?
The current price of XKRX:464280 is â‚©12950.00. The 52 week high of XKRX:464280 is â‚©60700.00 and 52 week low is â‚©11970.00.
When is next earnings date of TDS Pharm Co Ltd(XKRX:464280)?
The next earnings date of TDS Pharm Co Ltd(XKRX:464280) is .
Does TDS Pharm Co Ltd(XKRX:464280) pay dividends? If so, how much?
TDS Pharm Co Ltd(XKRX:464280) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers